The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.